Loading...
Market
How will Pfizer's stock price react within one month after the commercial launch of the Hemophilia A gene therapy?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 0% to 10% • 25%
No significant change • 25%
Decrease • 25%
Stock market data from sources like Yahoo Finance or Bloomberg
Story
Pfizer and Sangamo's AFFINE Study Shows Positive Phase 3 Results for Hemophilia A Gene Therapy
Jul 24, 2024, 11:02 AM
Pfizer has announced positive topline results from its Phase 3 study of a gene therapy candidate for Hemophilia A. The gene therapy, developed in collaboration with Sangamo Therapeutics, met its primary and key secondary objectives in the pivotal AFFINE study. This included a statistically significant reduction in annualized bleeding rates (ABR) from week 12 to month 15 post-infusion compared to routine factor VIII prophylaxis, with a reduction from 4.73 to 1.24 (p=0.0040). Despite these promising results, questions remain about the long-term durability and commercial viability of the therapy. Additionally, 84% of patients achieved more than 5% of normal factor VIII levels, although critical details about the use of immunosuppressants were not provided. Pfizer's gene therapy aims to offer a new treatment option for adults with moderately severe to severe Hemophilia A. Cash from Pfizer, however, is unlikely for another few months.
View original story
Similar markets
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Reduction by <25% • 25%
Reduction by 25-50% • 25%
Reduction by 50-75% • 25%
Reduction by >75% • 25%
Yes • 50%
No • 50%
Increases by more than 10% • 25%
Decreases by more than 10% • 25%
Changes by less than 10% • 25%
No significant change • 25%
Yes • 50%
No • 50%
Increase over 20% • 25%
Increase 0-20% • 25%
No change • 25%
Decrease • 25%
Increase by over 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by over 10% • 25%
Stock price increases by more than 10% • 25%
Stock price increases by less than 10% • 25%
Stock price remains stable • 25%
Stock price decreases • 25%
Stock rises by more than 10% • 25%
Stock rises by 0-10% • 25%
Stock falls by 0-10% • 25%
Stock falls by more than 10% • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Positive • 33%
Neutral • 33%
Negative • 34%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%